Group 1: Financial Performance - The company achieved a turnaround in 2024, primarily due to product structure optimization and increased marketing efforts, leading to stable revenue growth in the chemical drug sector [1] - The acquisition of 80% of Tianyuan Pharmaceutical contributed to revenue growth in the traditional Chinese medicine segment [1] - The company managed to reduce R&D investment compared to 2023 while maintaining a high level of overall R&D input [1][2] Group 2: R&D Strategy - In 2025, the R&D focus will be on chemical drugs, traditional Chinese medicine, and the health sector, aiming for technological innovation and market expansion [3] - The company received approval for "Silicone Oil Emulsion" and "Compound Polyethylene Glycol Electrolyte Powder (III)" in February 2025, enhancing its product pipeline in the digestive system field [3] - A strategic partnership with Anhui Chengqing Tang National Medicine Co., Ltd. aims to modernize traditional Chinese medicine production [3] Group 3: Subsidiary Operations - Shenzhen Yiwei Medical Technology Co., Ltd., a subsidiary, specializes in early screening, precise diagnosis, and rehabilitation for brain diseases, recognized as a national "little giant" enterprise [4] - Yiwei Medical's core products address stroke, Alzheimer's disease, cognitive disorders, and developmental disabilities, providing comprehensive solutions in the brain disease sector [5] Group 4: Business Model - Yiwei Medical offers a full-service model from screening to rehabilitation, creating a closed-loop medical service system [6] - The company collaborates with health check institutions to provide a comprehensive "brain routine" health check package [6] Group 5: International Expansion - The company has made significant progress in overseas markets, achieving full product line sales of contrast agents and obtaining EU GMP and Brazil ANVISA GMP certifications for its production line [7][8] - The company is accelerating the registration of contrast agent products for international markets, laying the groundwork for broader market expansion [8] Group 6: Acquisition Strategy - Recent acquisitions, such as Haichang Pharmaceutical and Tianyuan Pharmaceutical, have strengthened the company's competitive position in the contrast agent and traditional Chinese medicine markets [9] - Future acquisitions will align with the company's overall strategic development and business growth needs, adhering to regulatory requirements [9]

Group 1: Company Performance - The company achieved profitability in 2024, driven by product structure optimization and increased marketing efforts, leading to stable revenue growth in the chemical drug sector [1] - The acquisition of 80% of Tianyuan Pharmaceutical contributed to revenue growth in the traditional Chinese medicine segment [1] - R&D investment remained high but decreased compared to 2023, with no goodwill impairment recorded in the current reporting period [1] Group 2: Marketing Strategies - The marketing strategy for Jiuwu Zhenxin Granules will be adjusted following the change in the National Medical Insurance Drug List, which now limits its use to "generalized anxiety disorder with heart and spleen deficiency" [2] - The company is developing a series of health products targeting sleep disorders in young and elderly populations, currently under review for approval [2] Group 3: Subsidiary Developments - Shenzhen Yiwei Medical Technology Co., Ltd. is recognized as a national-level "little giant" enterprise, focusing on early screening and treatment of brain diseases with AI technology [3] - Yiwei Medical's core products include AI software for early Alzheimer's diagnosis and a comprehensive stroke diagnosis platform, both of which have received multiple certifications [4][5] Group 4: Gene Technology Progress - Shihe Gene achieved profitability in 2023 and is progressing towards an IPO, with a focus on automated NGS solutions for clinical applications [6] - The company has received FDA breakthrough device designation for its multi-cancer early screening product and is expanding its global presence [6][7] Group 5: International Market Expansion - The company has successfully achieved overseas sales for its entire line of contrast agents and has received EU GMP and Brazil ANVISA GMP certifications for its production facilities [8][9] - Ongoing efforts to expedite the registration of contrast agent products for international markets are underway, enhancing the company's global business channels [9]